Management of hereditary angioedema: 2010 Canadian approach

C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowen, Tom, Brosz, John, Brosz, Kristylea, Hebert, Jacques, Ritchie, Bruce
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921103/
https://www.ncbi.nlm.nih.gov/pubmed/20667123
http://dx.doi.org/10.1186/1710-1492-6-20
Descripción
Sumario:C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Conference on the diagnosis, therapy and management of HAE. We have formed the Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'Angioédème Héréditaire (RCAH) - http://www.haecanada.com to advance care of patients with this disorder in Canada. We here present a review of management of HAE in Canada.

Ejemplares similares